Irbesartan Sandoz

Irbesartan, the active ingredient in Irbesartan Sandoz, is an angiotensin II receptor blocker presented as a tablet for oral use. Approved in the European Union, it treats hypertension and diabetic nephropathy in adult patients.

GNH USA supplies Irbesartan Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan is used to manage conditions that involve the renin‑angiotensin system.

- Hypertension: reduces elevated blood pressure and lowers cardiovascular risk. - Diabetic nephropathy: slows progression of kidney damage associated with diabetes.

Irbesartan may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Dizziness - Headache - Fatigue - Abdominal discomfort - Nasal congestion - Elevated serum potassium

Serious or Rare Side Effects: - Angioedema - Severe hyperkalemia - Acute renal failure - Hepatic injury - Hypotensive shock - Neutropenia

When prescribing Irbesartan, clinicians should observe several safety considerations.

- Blood pressure monitoring: check regularly to avoid hypotension. - Renal function assessment: evaluate serum creatinine and eGFR before and during therapy. - Serum potassium surveillance: monitor for hyperkalemia, especially with potassium‑sparing agents. - Pregnancy caution: avoid use during pregnancy due to potential fetal harm. - Elderly dose adjustment: start with lower dose in older patients with renal impairment. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Irbesartan can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Concomitant use with aliskiren in diabetic patients: increased risk of renal impairment. - Dual therapy with ACE inhibitors or other ARBs: heightened risk of hypotension and hyperkalemia. - Potassium‑sparing diuretics (e.g., spironolactone): may cause dangerous hyperkalemia. - NSAIDs in patients with compromised renal function: can reduce antihypertensive effect and worsen kidney function.

Moderate Interactions (Monitor Closely): - Lithium: may increase lithium levels, requiring serum monitoring. - Cyclosporine: can raise cyclosporine concentrations. - Non‑steroidal anti‑inflammatory drugs: may attenuate blood‑pressure control. - Diuretics (thiazides): may enhance hypotensive effect. - Rifampin: may lower Irbesartan plasma concentrations.